pamf.org

Palo Alto Medical Foundation Newsroom


PAMFRI’s Zhao to Receive Award at SAS Global Forum

Every year, users of Statistical Analysis System (SAS) software meet at the international SAS Global Forum. This year, Beinan Zhao, MS, senior statistician at the Palo Alto Medical Foundation Research Institute (PAMFRI), will present recent research at the 2013 SAS Global Forum, taking place April 29 to May 1, in San Francisco, Calif. 

Beinan Zhao, MS, is a senior statistician with the PAMF Research Institute.

At this year’s conference, Zhao will be receiving a Junior Professional Award for her work on an abstract titled “Estimating Patient Adherence to Medication with Electronic Health Records Data and Pharmacy Claims Combined.”

Zhao has conducted statistical analysis and data management using SAS software in health policy, patient outcomes and clinical research studies as a member of the DISCOVER team at PAMFRI.  Her work focuses on utilizing de-identified data from Electronic Heath Records (EHRs) in chronic disease epidemiology research.  She is examining racial/ethnic disparities with regards to type 2 diabetes and cardiovascular risk factors for the Pan-Asian Cohort Study (PACS). PACS is a five-year study funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and led by PAMFRI’s Latha Palaniappan, M.D., which is researching diabetes and its risk factors among Asian American subgroups. 

Zhao has developed a series of comprehensive measurements for patient medication adherence, which is fundamental in understanding patient behavior in taking medications and its relationship to disease outcomes. 

Through the PACS study, the DISCOVER team is comparing the efficacy of oral drugs for treatment of type 2 diabetes among Asian subgroups.  It is well known that type 2 diabetes manifests differently in racial/ethnic groups, who may respond differently to the same pharmacotherapy.  The PACS cohort allows for comparative effectiveness research on diabetes medications among Asian subgroups, as well as the ability to study existing preferences for certain drugs among patients and physicians.